RMDC has concluded a joint research agreement with Tokyo Medical University to develop stem cell culture technology for regenerative medicine, aiming to create new culture devices. The research period is from July 2026 to June 2027, collaborating with the world-renowned Professor Ochiya to enhance technological capabilities in the regenerative medicine business.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3840","jir_company_name":"PATH","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-21","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/3840-20260721-01.pdf","jir_short_summary":"RMDC has concluded a joint research agreement with Tokyo Medical University to develop stem cell culture technology for regenerative medicine, aiming to create new culture devices. The research period is from July 2026 to June 2027, collaborating with the world-renowned Professor Ochiya to enhance technological capabilities in the regenerative medicine business.","jir_summary":"### Overview of Business Activities\nRMDC has entered into a research contract with Tokyo Medical University to develop stem cell culture technology for use in regenerative medicine. The research period runs from July 1, 2026, to June 30, 2027, leveraging insights from the globally renowned Professor Ochiya to optimize extracellular vesicles and culture devices. This aims to improve technological capabilities in the regenerative medicine field and strengthen our business foundation.\n\n### Future Outlook and Impact on the Company\nWhile this research is expected to contribute to medium- to long-term corporate value and business expansion, its impact on the consolidated results for the fiscal year ending March 2027 is anticipated to be minimal. Going forward, sharing research\u6210\u679c and rights is expected to strengthen competitiveness in regenerative medicine related businesses and provide a foundation for new business development.","jir_financial_highlights":"","jir_category":"","jir_hashtags":"#PATH #IRRelated #JapaneseStocks","jir_key_figures":"Research Period: July 1, 2026 to June 30, 2027\nJoint Research Partners: Tokyo Medical University Institute of Medical Science and RMDC Hyogo CPF\nResearch Contract Signing Date: July 21, 2026","jir_meta_title":"\u3010Company Name\u3011Regenerative Medicine Research Agreement | July 2026","jir_meta_description":"RMDC has jointly signed a research agreement with Tokyo Medical University for stem cell culture technology for regenerative medicine. Aiming to develop new culture devices and strengthen the business foundation.","jir_og_title":"\u3010Company Name\u3011Regenerative Medicine Research Agreement | July 2026","jir_og_description":"RMDC has entered into a joint research agreement with Tokyo Medical University to enhance regenerative medicine technology and expand business. The research period is from July 2026 to June 2027.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60203,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-86171","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n